Sugi Predict

Sugi Predict / Compounds / SCHEMBL6377271

SCHEMBL6377271

SCHEMBL6377271

Brc1cccc2c1C(c1ccccc1)c1ccccc1-2

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK1 P28482 3/20 0.39
▸ HTR2B P41595 3/20 0.39
▸ CYP1A2 P05177 2/20 0.39
▸ LMNA P02545 1/20 0.39
▸ TP53 P04637 1/20 0.39
▸ CYP3A4 P08684 1/20 0.39
▸ MAPT P10636 1/20 0.39
▸ GID4 Q8IVV7 1/20 0.39
▸ ALDH1A1 P00352 2/20 0.38
▸ ADRA2C P18825 1/20 0.36
▸ PTGS2 P35354 1/20 0.36
▸ HRH1 P35367 1/20 0.36
▸ HTR3A P46098 1/20 0.36
▸ PDE4D Q08499 1/20 0.36
▸ HTR2A P28223 2/20 0.35
▸ KDM1A O60341 1/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ NPC1 O15118 1/20 0.35
▸ GAA P10253 1/20 0.35
▸ KMT2A Q03164 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29167764 0.85 ALDH1A1 (0.48) MAPK1HTR2BCYP1A2LMNATP53
SCHEMBL16544752 0.84 ALDH1A1 (0.50) MAPK1HTR2BTP53MAPTGID4
SCHEMBL29167758 0.82 MAPK1 (0.46) MAPK1HTR2BCYP1A2LMNATP53
SCHEMBL29447800 0.82 MAPK1 (0.37) MAPK1HTR2BCYP1A2LMNATP53
SCHEMBL28692344 0.80 ADRA2C (0.37) MAPK1HTR2BCYP1A2LMNATP53
SCHEMBL27210317 0.80 ADRA2C (0.38) MAPK1HTR2BCYP1A2LMNATP53
SCHEMBL29167759 0.80 ALDH1A1 (0.37) MAPK1HTR2BCYP1A2LMNATP53
SCHEMBL27947294 0.80 MEN1 (0.42) MAPK1HTR2BCYP1A2LMNATP53
SCHEMBL115552 0.79 ALDH1A1 (0.44) MAPK1HTR2BCYP1A2LMNATP53
SCHEMBL29377413 0.79 ALDH1A1 (0.44) MAPK1HTR2BCYP1A2LMNATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109665938-A A kind of -9 ' of bromo- 9- methyl of 4--phenyl fluorenes production method 河南省科学院化学研究所有限公司 2019-04-23 — — CN claimed
CN-107573208-A A kind of synthetic method of the phenyl fluorenes of 9 bromine of high-purity 9 阿拉丁试剂（上海）有限公司 2018-01-12 — — CN claimed
CN-107011132-A Aromatic compound containing side chain 味之素株式会社 2017-08-04 — — CN claimed
CN-110291067-A Compound, coating composition comprising the same, organic light emitting device using the same, and method of manufacturing the same 株式会社LG化学 2019-09-27 — — CN disclosed
CN-109863133-A Fluorene-based compound, organic light emitting device using the same, and method of manufacturing the same 株式会社LG化学 2019-06-07 — — CN disclosed
CN-109843850-A Fluorene-based compound, organic light emitting device using the same, and method of manufacturing the same 株式会社LG化学 2019-06-04 — — CN disclosed
CN-109665938-A A kind of -9 ' of bromo- 9- methyl of 4--phenyl fluorenes production method 河南省科学院化学研究所有限公司 2019-04-23 — — CN disclosed
CN-106588739-B A kind of trans- 3- hydroxy-L-proline preparation method 武汉恒和达生物医药有限公司 2019-03-05 — — CN disclosed
CN-108430992-A QUINOLINE-3-CARBOXAMIDES AS H-PGDS INHIBITORS 阿斯特克斯医疗公司 2018-08-21 — — CN disclosed
CN-107573208-A A kind of synthetic method of the phenyl fluorenes of 9 bromine of high-purity 9 阿拉丁试剂（上海）有限公司 2018-01-12 — — CN disclosed
US-9818948-B2 Carbazole derivatives for organic electroluminescence devices MERCK PATENT GMBH (DE) 2017-11-14 — — US disclosed
CN-102712623-B Hepatitis c virus inhibitors BRISTOL MYERS SQUIBB CO 2014-04-02 — — CN disclosed
CN-102395579-B Hepatitis c virus inhibitors BRISTOL MYERS SQUIBB CO 2014-03-12 — — CN disclosed
US-20050187138-A1 Peptide beta-strand mimics based on pyridinones, pyrazinones, pyridazinones, and triazinones THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, A CALIFORNIA CORPORATION (US) 2005-08-25 — — US disclosed
EP-0457324-B1 Heterocyclic-NMDA antagonists MERRELL DOW PHARMA (US) 1995-12-06 — — EP disclosed
US-5470844-A Heterocyclic-NMDA antagonists MERRELL DOW PHARMACEUTICALS INC. (US) 1995-11-28 — — US disclosed
CN-1027695-C Heterocyclic-NMDA antagonists MERRELL DOW PHARMA (US) 1995-02-22 — — CN disclosed
US-5194430-A HETEROCYCLIC-NMDA ANTAGONISTS MERRELL DOW PHARMACEUTICALS INC. (US) 1993-03-16 — — US disclosed
CN-1056499-A HETEROCYCLIC-NMDA ANTAGONISTS MERRELL DOW PHARMA (US) 1991-11-27 — — CN disclosed
EP-0457324-A1 Heterocyclic-NMDA antagonists MERRELL DOW PHARMACEUTICALS INC. (US) 1991-11-21 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050187138-A1 Peptide beta-strand mimics based on pyridinones, pyrazinones, pyridazinones, and triazinones IAPP, GLP1R, PAM MAPK1 3355/4885HTR2B 604/4885CYP1A2 4190/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.